Oncology – Head and Neck
Review | Updated salivary gland immunohistochemistry
5 May, 2023 | 14:55h | UTCUpdated Salivary Gland Immunohistochemistry: A Review – Archives of Pathology & Laboratory Medicine
RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation
29 Mar, 2023 | 13:05h | UTCResults of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)
Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology
Commentaries:
Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive
RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma
22 Mar, 2023 | 13:12h | UTCHyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Feasibility and efficacy of microwave ablation in the treatment of papillary thyroid microcarcinoma: a prospective cohort study
14 Mar, 2023 | 13:30h | UTCMicrowave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study – Radiology (link to abstract – $ for full-text)
RCT | Medial retropharyngeal nodal region sparing radiotherapy vs. standard radiotherapy in patients with nasopharyngeal carcinoma
7 Feb, 2023 | 14:09h | UTC
Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27 Jan, 2023 | 12:16h | UTC
RCT | Nivolumab plus Ipilimumab vs. EXTREME regimen as first-line treatment for recurrent/metastatic head and neck cancer
19 Jan, 2023 | 13:41h | UTC
NICE Guideline | Thyroid cancer: assessment and management
11 Jan, 2023 | 14:34h | UTCThyroid cancer: assessment and management – National Institute for Health and Care Excellence
ASCO Guideline | Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers
9 Jan, 2023 | 14:41h | UTCNews Release: ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer – ASCO Daily News
Cohort Study | Lobectomy vs. total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis.
6 Dec, 2022 | 13:41h | UTCComparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis – JAMA Surgery (free for a limited period)
Invited Commentary: Is Lobectomy as Effective as Total Thyroidectomy in Treating Patients With Intermediate-Risk Papillary Thyroid Carcinoma With Lateral Lymph Node Metastasis? – JAMA Surgery (free for a limited period)
Commentary on Twitter
Study of patients with papillary thyroid carcinoma and lymph node metastases found that recurrence-free survival was similar after lobectomy and total #thyroidectomy. https://t.co/07mMcczp1T
— JAMA Surgery (@JAMASurgery) December 1, 2022
Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.
25 Nov, 2022 | 12:42h | UTCGLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)
Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist
RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.
7 Nov, 2022 | 12:26h | UTCLow-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Low-Dose Immunotherapy has made immunotherapy more accessible, and has brought down the cost of therapy from 60-80 lakhs to below 5.0 lakhs per year. Hugh cost saving. A step towards atmanirbhar Bharat. @PMOIndia @TOIIndiaNews @ndtv @ZeeNews @the_hindu https://t.co/c0WuC9Wlfk
— Dr. Vijay Patil (@DrVijayPatil11) October 21, 2022
2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.
27 Oct, 2022 | 12:33h | UTCCommentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)
RCT | Adjuvant capecitabine following concurrent CTX-RT in locoregionally advanced nasopharyngeal carcinoma.
17 Oct, 2022 | 12:15h | UTC
4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.
14 Oct, 2022 | 14:11h | UTCOriginal Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Guideline Summary | Recommendations for care of survivors of head and neck cancer.
7 Oct, 2022 | 14:15h | UTCRecommendations for Care of Survivors of Head and Neck Cancer – JAMA (free for a limited period)
Original Guideline: Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology
Related:
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.
3 Oct, 2022 | 13:42h | UTCCommentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser
Commentary on Twitter
❎ ASTRA trial: Radioactive iodine ± selumetinib doesn't improve remission rates for high-risk #thyroidcancer
✅ Postoperative pathologic risk stratification identified pts at risk of primary treatment failurehttps://t.co/kvakaMXtDh#JCO #thycsm @MSKCancerCenter pic.twitter.com/mvQwgzIjWh— Journal of Clinical Oncology (@JCO_ASCO) March 16, 2022
M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.
21 Sep, 2022 | 13:07h | UTCProphylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)
Noninferiority RCT | Induction chemotherapy regimen of docetaxel plus cisplatin vs. docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
6 Sep, 2022 | 14:29h | UTC
Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.
1 Sep, 2022 | 11:53h | UTC
RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.
25 Aug, 2022 | 12:13h | UTCEffect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)
Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA
The contemporary management of cancers of the sinonasal tract in adults.
16 Aug, 2022 | 13:39h | UTC
Guideline | Pediatric differentiated thyroid carcinoma.
29 Jul, 2022 | 12:31h | UTC
Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.
19 Jul, 2022 | 12:58h | UTCDeintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Commentary on Twitter
Less is more? 🤔 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels < 4000.QOL & toxicity improved w/ less chemo https://t.co/XovHi2P06W pic.twitter.com/JJqiC8wnWW
— Journal of Clinical Oncology (@JCO_ASCO) January 25, 2022
Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children.
8 Jul, 2022 | 11:20h | UTC
Commentaries on Twitter
A multigene classifier reveals that malignant pediatric thyroid nodules have a unique molecular landscape vs those in adults. The classifier had a sensitivity of 96% & specificity of 78% for cancer detection & might reduce the need for diagnostic surgery: https://t.co/hdsPjGe9IR
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Pediatric thyroid cancer is on the rise. Its genomic landscape is unique; but, this retrospective case series shows that it may still be amenable to molecular classification—potentially decreasing diagnostic surgery & opening avenues for targeted therapy. https://t.co/KiYMsB1qGM
— JAMA Oncology (@JAMAOnc) June 10, 2022